Phage Therapy Enhanced by Using Engineered Bacteriophages: A Powerful Antibacterial Tool to Address the Dilemma Posed by Multidrug-Resistant Bacterial Infections
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27167103 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Xuanliang Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China. Hauptthemen laut MEDLINE: Phage Therapy, Bacteriophages, Bacterial Infections, Drug Resistance, Multiple, Bacterial. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Gdansk.
Abstract (Originalsprache)
The continuous slowdown in the research and development of new antibiotics and antibiotic overuse have turned the problem of antibacterial resistance into a global public health crisis. As a very promising alternative to multi-drug-resistant bacterial infection, phage therapy is receiving renewed attention. However, the inherent biological limitations of natural phages restrict their extensive clinical application. This review examines how synthetic biology can be harnessed to transform phages and to build the next generation of antibacterial therapies. We outline the main advantages of natural phages, including high host specificity, self-amplification, bactericidal activity and the ability to degrade biofilms. We also point out the bottlenecks of clinical applications of bacteriophages, such as narrow host range, rapid removal in the body and potential genetic safety risks. Moreover, we elaborate on the core synthetic biological tools used to overcome the above limitations, including CRISPR-Cas gene editing, receptor-binding protein reprogramming, functional load delivery and immunogenic regulation, and summarize the recent clinical progress and personalized treatment process. The increasing clinical evidence shows that synthetic biology can effectively overcome the inherent defects of natural bacteriophages, confirming the safety and initial efficacy of bacteriophage therapy. Engineered phages provide a practical strategy to meet the antimicrobial resistance challenge. Clinical applications of such phages will mainly depend on progress in production standardization, regulatory framework construction and scientific and reasonable joint treatment program development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China.
- Institute for Research in Molecular Medicine, Universiti Sains Malaysia, Pulau Pinang 11800, Malaysia.
- Laboratory of Bacteriophage Biology and Biotechnology, Department of Molecular Biology, Faculty of Biology, University of Gdansk, Wita Stwosza 59, 80-308 Gdansk, Poland.
ORCID-Profile: Theam Soon Lim, Grzegorz Węgrzyn
Förderung
- University of Gdansk
Zitieren
APA
Wang, X., Zhou, H., Lim, T. S., & Węgrzyn, G. (2026). Phage Therapy Enhanced by Using Engineered Bacteriophages: A Powerful Antibacterial Tool to Address the Dilemma Posed by Multidrug-Resistant Bacterial Infections. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27167103
Vancouver
Wang X, Zhou H, Lim TS, Węgrzyn G. Phage Therapy Enhanced by Using Engineered Bacteriophages: A Powerful Antibacterial Tool to Address the Dilemma Posed by Multidrug-Resistant Bacterial Infections. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27167103
BibTeX
@article{Wang2026,
author = {Wang, Xuanliang and Zhou, Haolin and Lim, Theam Soon and Węgrzyn, Grzegorz},
title = {Phage Therapy Enhanced by Using Engineered Bacteriophages: A Powerful Antibacterial Tool to Address the Dilemma Posed by Multidrug-Resistant Bacterial Infections},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27167103}
}
EUVIMED